Endothelial ferroptosis blockade targets ischemic stroke and neurodegenerative conditions in brain microvascular endothelial cells

Photo by Bhautik Patel / Unsplash

Frontiers in Medicine Published June 6, 2026 Medically reviewed June 6, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that endothelial ferroptosis blockade requires further evaluation in human systems and for safety.

This narrative review examines the potential of endothelial ferroptosis blockade for treating ischemic stroke, neurodegenerative conditions, and inflammatory conditions. The discussion focuses on brain microvascular endothelial cells as the primary cellular model for investigation. The authors do not report specific sample sizes, settings, or primary outcomes for the evidence presented. Instead, the text synthesizes the current conceptual landscape regarding this intervention mechanism.

The authors identify several critical limitations that must be addressed before clinical application. They state that BMEC-specific models are needed to better understand the biology. Furthermore, human blood-brain barrier systems are required to validate findings from current models. The review also calls for the development of endothelial ferroptosis biomarkers to monitor therapeutic response. Additionally, BMEC-targeted delivery approaches need evaluation to ensure efficacy without off-target effects.

Finally, the authors caution that the physiological risks of systemic or prolonged ferroptosis blockade need careful evaluation. The review concludes that these gaps and limitations define the current state of knowledge. Clinicians should interpret these findings as preliminary concepts rather than established clinical data, given the lack of reported safety events or trial results.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation. In the central nervous system (CNS), most ferroptosis research has focused on neurons and glial cells, whereas the vulnerability of brain microvascular endothelial cells (BMECs) and its consequences for blood–brain barrier (BBB) integrity remain less clearly defined. Because BMECs form the vascular interface between the circulation and the brain parenchyma, ferroptotic injury in this cell population may represent an immunovascular mechanism through which endothelial redox stress is translated into barrier dysfunction and neuroinflammatory amplification. In this review, we summarize molecular pathways that may promote or restrain BMEC ferroptosis, including iron handling, antioxidant defense mediated by the solute carrier family 7 member 11 (SLC7A11)–glutathione peroxidase 4 (GPX4) axis and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, lipid peroxidation, and junctional remodeling. We then discuss how ferroptosis-associated endothelial injury may contribute to BBB leakage, damage-associated molecular pattern release, innate immune sensing, leukocyte recruitment, glial activation, and self-amplifying inflammatory feedback at the neurovascular interface. We organize the available literature according to the strength and cellular specificity of evidence, separating BMEC-specific findings, BBB-focused in vivo studies, indirect CNS evidence, and mechanistic analogies from non-CNS endothelial systems. Finally, we evaluate disease-specific evidence in ischemic stroke and selected neurodegenerative or inflammatory conditions, together with therapeutic strategies, BMEC-targeting considerations, candidate clinical biomarkers, and translational barriers for modulating endothelial ferroptosis. This review frames endothelial ferroptosis as a promising but incompletely established immunovascular link between BBB dysfunction and neuroinflammation, and highlights the need for BMEC-specific models, human BBB systems, endothelial ferroptosis biomarkers, biomarker-guided monitoring, BMEC-targeted delivery approaches, and careful evaluation of the physiological risks of systemic or prolonged ferroptosis blockade.